CardioDx to Present Results from Two Studies Evaluating the Clinical Utility of a Gene Expression Test for Obstructive Coronary Artery Disease
QCOR and SGIM Meeting Presentations Assess Role of Corus CAD Test Results in Clinical Decision-Making
PALO ALTO, Calif. – May 7, 2012 – CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced that data from two studies evaluating the effect of the Corus® CAD gene
expression test on clinician decision-making for patients with suspected obstructive coronary artery disease will be presented at two upcoming conferences.
On Wednesday, May 9, from 5:00 to 6:30 p.m. ET, John McPherson, M.D., director of the Cardiovascular Intensive Care Unit at Vanderbilt University Medical Center, in Nashville, Tenn., will
present “Improved Diagnostic Work-up of Patients Presenting to the Cardiologist with Symptoms of Suspected Obstructive Coronary Artery Disease: Results from the IMPACT (Investigation of a Molecular Personalized Coronary Gene Expression Test on Cardiology Practice Pattern) Trial” at the Quality of Care and Outcomes Research (QCOR) 2012 Scientific Sessions, which will be held May 9- 11, 2012, at the Omni Hotel at CNN Center in Atlanta, Ga.
The prospective IMPACT trial was designed to assess the effect of Corus CAD test scores on clinical decision-making on the assessment of stable patients referred to cardiologists for evaluation of chest pain and related symptoms suggestive of obstructive coronary artery disease. IMPACT enrolled 83 nondiabetic patients referred to Vanderbilt University Medical Center cardiologists. The cardiologists’ diagnostic strategies were evaluated before and after the Corus CAD score was known.
On Friday, May 11, from 11:30 a.m. to 1:00 p.m. ET, principal investigator Michael Conlin, M.D., of Johns Creek Primary Care, Suwanee, Ga., will present “The Use of a Personalized Gene Expression Test to Improve Decision Making in the Evaluation of Patients with Suspected Coronary Artery Disease” at the Society of General Internal Medicine (SGIM) 35th Annual Meeting taking place May 9-12, 2012 at the Walt Disney World Swan and Dolphin Resort in Orlando, Fla.
Dr. Conlin’s study evaluated the impact of the Corus CAD test in real-world clinical practice on 317 patients at four community-based primary care clinics in Arizona, Georgia, Louisiana and North
Carolina. The objective of the study was to assess the role of low (≤15) and non-low (>15) Corus CAD test scores on patient referrals to cardiologists by primary care providers in stable nondiabetic patients with symptoms suggestive of coronary artery disease. Additionally, a secondary analysis was performed to evaluate the use of noninvasive and invasive cardiac testing in both low- and non-lowscoring Corus CAD patient groups.
About Corus CAD
With a simple blood draw, Corus CAD can help primary care clinicians and cardiologists exclude obstructive coronary artery disease as the cause of a stable non-diabetic patient's symptoms. It is the first sex-specific test for obstructive coronary artery disease, accounting for critical biological differences between men and women. The test is safe and does not expose patients to radiation risks or imaging agent intolerance.
The Corus CAD test measures the RNA levels of 23 genes. Because these blood RNA levels are altered when obstructive coronary artery disease is present, the Corus CAD score aids clinicians in
assessing whether an individual patient’s symptoms may be due to obstructive coronary artery disease.
Corus CAD is commercially available through an innovative patient sample kit that includes everything needed for blood collection and express delivery to the company’s CLIA-certified Palo Alto, Calif.
laboratory. Test results are delivered promptly to the clinician’s office. Corus CAD is currently available in the United States.
Corus CAD has been recognized by The Wall Street Journal’s Technology Innovation Awards, honored as a Gold Edison Award recipient, and named one of TIME’s Top Ten Medical Breakthroughs.
For more information please visit http://www.cardiodx.com/media-kit/.
CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, is committed to developing clinically validated tests that empower clinicians to better tailor care to each individual patient. Strategically focused on coronary artery disease, cardiac arrhythmia and heart failure, CardioDx is poised to expand patient access and improve healthcare quality and efficiency through the commercialization of genomic technologies. For more information, please visit www.cardiodx.com.